SCHEMBL10189273

SCHEMBL10189273

COc1ccc(-c2csnc2-c2cc(C)c3c(c2)OCO3)c(OP(=O)(O)O)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.35
APP P05067 1/20 0.35
KDM4E B2RXH2 5/20 0.33
MAPT P10636 5/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
LMNA P02545 3/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
EDNRA P25101 5/20 0.32
EDNRB P24530 4/20 0.32
BCHE P06276 2/20 0.32
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL618634 0.92 KDM4E (0.41) ACHEAPPKDM4EMAPTMEN1
SCHEMBL10189279 0.85 GRB2 (0.32) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL10189261 0.85 MAPT (0.39) ACHEAPPKDM4EMAPTMEN1
SCHEMBL12339071 0.85 ACHE (0.36) ACHEAPPKDM4EMAPTMEN1
SCHEMBL10189275 0.83 EDNRB (0.37) ACHEKDM4EMAPTMEN1KMT2A
SCHEMBL10189271 0.82 ACHE (0.37) ACHEAPPKDM4EMAPTMEN1
SCHEMBL10189247 0.81 PDGFRB (0.36) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL615454 0.80 KMT2A (0.42) ACHEAPPKDM4EMAPTMEN1
SCHEMBL10189280 0.80 NPC1 (0.32) NPC1RAB9A
SCHEMBL618851 0.79 PDGFRB (0.40) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ACHE 4837/4885APP 4674/4885KDM4E 2492/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ACHE 4837/4885APP 4674/4885KDM4E 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.